Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Viking Therapeutics, Inc. (VKTX)
A forensic read on Viking Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
7.0
Altman Z-score
Clean
Earnings quality
2
Forensic signals
-71.3%
ROE
$4.4B
Market cap
Viking Therapeutics, Inc. earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is 7.0, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-66%Return on invested capital.Return on invested capital is -66% and slipping from -51% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+15.5%/yrShare-count dilution.Diluted share count changed +47% over the last 3 years to FY2025 (+15.5%/yr). The count is GROWING — existing holders are being diluted. That's ~15.5% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~47%.
Key fundamentals
Return on Equity-56.3%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Viking Therapeutics, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about VKTX's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown